Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 13, 2017. The document serves as a transaction notification reporting share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. These transactions were executed on the London Stock Exchange (XLON) on January 12, 2017.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share transactions with the following parameters:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £15.7338 per share for all reported transactions.
- Transaction Nature: Acquisition of shares via dividend re-investment under the Company's ShareReward Plan.
- Total Volume: 364 shares acquired across 11 individuals.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It reports routine compliance disclosures regarding the increase in shareholdings of specific executives due to dividend re-investment plans.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider share transactions.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs (364 shares) against the company's broader insider trading reports.
- Confirm the dividend payment date of January 12, 2017, to validate the timing of the re-investment.
- Review the ShareReward Plan terms to understand the mechanics of the dividend re-investment.
- Note that this filing contains no operational or financial performance data; refer to Form 20-F for comprehensive financial metrics.